There are currently 591 clinical trials in Sacramento, California looking for participants to engage in research studies. Trials are conducted at various facilities, including University of California Davis Comprehensive Cancer Center, University of California Davis Medical Center, University Of California Davis and Sutter Medical Center Sacramento. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
NCT04665947
Recruiting
This is a Phase I, first-in-human study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or metastatic pancreatic adenocarcinoma (PDAC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/18/2024
Locations: University of California Davis, Sacramento, California
Conditions: Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
Register for Updates
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
NCT04587687
Recruiting
This phase II trial investigates how well brentuximab vedotin and bendamustine work in treating patients with follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Chemotherapy drugs, such as bendamustine, work in different ways to stop the growth of can... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/18/2024
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Register for Updates
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
NCT06211335
Recruiting
This phase Ib trial tests the safety, side effects and how well losartan, pembrolizumab and stereotactic body radiation therapy (SBRT) for the treatment of patients with head and neck squamous cell carcinoma that has come back to nearby tissue or lymph node after a period of improvement (locally recurrent), that has not responded to previous treatment (refractory) or that has spread from where it first started to multiple other placed in the body (oligometastatic). Losartan is a drug used to tre... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/08/2024
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Locally Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma
Register for Updates
Coflex PS3 Actual Conditions for Use Study
NCT02555280
Recruiting
A 2 and 5 year evaluation of clinical outcomes in the treatment of degenerative spinal stenosis with concomitant low back pain by decompression with additional stabilization using the coflex® Interlaminar Technology for FDA Actual Conditions of Use Study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2024
Locations: Sutter Health, Sacramento, California
Conditions: Spinal Stenosis Lumbar
Register for Updates
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
NCT03941379
Recruiting
The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care therapy, etc.) while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and effectiveness in these subjects. This study will collect information from procedures conducted as part of routine follow-up eye care and cancer care. Additionally, the registry will collect all adverse... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2023
Locations: Retina Consultants of Sacramento, Sacramento, California
Conditions: Choroidal Melanoma, Indeterminate Lesions of Eye
Register for Updates
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
NCT05423691
Recruiting
To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2023
Locations: UC Davis Health, Sacramento, California
Conditions: Myelofibrosis
Register for Updates
Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis
NCT06074315
Recruiting
This is a Pre-IDE, prospective, multicenter, randomized, parallel-group, double-blind, vehicle- controlled study to evaluate safety and effectiveness of Nail Genesis DLSO Product for the treatment of DLSO compared with vehicle in infected great toenails in a total of 338 males and non-pregnant, non-lactating, females between 18 and 65 years of age (inclusive). Subjects will be randomized in a 2:1 ratio to receive either Nail Genesis DLSO Product or vehicle. Subject eligibility will be determine... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/06/2023
Locations: Northern California Research, Sacramento, California
Conditions: Distal Lateral Subungual Onychomycosis, Onychomycosis
Register for Updates
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer
NCT02935205
Recruiting
This phase I/II trial studies the side effects of enzalutamide and indomethacin and to see how well they work in treating patients with prostate cancer that does not respond to treatment with hormones, has come back, or has spread from where it started to other places in the body. Androgens can cause the growth of prostate cancer cells. Hormone therapy using enzalutamide and indomethacin may fight prostate cancer by lowering the amount of androgen the body makes and/or blocking the use of androg... Read More
Gender:
MALE
Ages:
19 years and above
Trial Updated:
11/28/2023
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Register for Updates
Point-of-Care Ultrasound for Pediatric Thoracic Trauma: A Multi-Institutional Trial
NCT05025150
Recruiting
The objective of the proposed study is to investigate the diagnostic accuracy of ED POCUS in pediatric traumatic thoracic injuries including traumatic pneumothorax, hemothorax, lung contusion, rib fractures, and pulmonary edema (from submersion injury). This will be a prospective, multicenter, observational study of children 0-21 years of age presenting to the participating pediatric emergency departments for suspected traumatic thoracic injury. Results of POCUS will be compared to that of chest... Read More
Gender:
ALL
Ages:
Between 0 years and 21 years
Trial Updated:
11/26/2023
Locations: Sutter Medical Center Sacramento, Sacramento, California
Conditions: Trauma Chest, Pediatric ALL
Register for Updates
Treatment of PAF With the Synaptic System
NCT05905835
Recruiting
Enrolled subjects will be treated with the Synaptic Cryoablation System. Treatment will include cryoablation of the pulmonary veins to achieve PVI. All subjects will be followed for twelve (12) months after completion of the index ablation procedure.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/09/2023
Locations: Mercy General Hospital, Sacramento, California
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
NCT06103682
Recruiting
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/27/2023
Locations: University of California, Davis, Sacramento, California
Conditions: Non-small Cell Lung Cancer, Oligoprogressive, Small-cell Lung Cancer
Register for Updates
Patient-Derived Xenografts to Reduce Cancer Health Disparities
NCT04410302
Recruiting
This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.
Gender:
ALL
Ages:
Between 21 years and 100 years
Trial Updated:
10/12/2023
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Bladder Carcinoma, Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma, Malignant Neoplasm
Register for Updates